Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott.
Here’s Whether Investors Should Follow His Lead
Ken Griffin recently boosted stakes in AbbVie (NYSE: ABBV) and Abbott Laboratories (NYSE: ABT), according to his latest 13F. Griffin is the billionaire founder and CEO of the hedge fund company Citadel. Arguably one of the sharpest minds in the hedge-fund world, he is leaning into two healthcare machines that sit right at the intersection of science and steady cash; that’s a signal worth thinking about.
Griffin’s portfolio holds over 1,000 positions and hundreds of billions of dollars. He can put money almost anywhere. Yet he raised his exposure to AbbVie, a drug developer built on immunology and oncology, and Abbott, a device and diagnostics giant embedded in hospitals and homes across the globe.